A new ultrasound-based device can effectively treat peripheral arterial occlusion and deep vein thrombosis in record time, according to a multicenter study presented at the 2006 International Symposium on Endovascular Therapy in Miami Beach.
A new ultrasound-based device can effectively treat peripheral arterial occlusion and deep vein thrombosis in record time, according to a multicenter study presented at the 2006 International Symposium on Endovascular Therapy in Miami Beach.
An untreated thrombus causing peripheral arterial occlusive disease or DVT may lead to foot or leg amputation, pulmonary embolism, and death. The new ultrasound-enhanced thrombolysis system could improve therapy by allowing physicians to begin heparin, alteplase, or urokinase infusion in half the time usually required for recanalization.
"This is a big step forward," said principal investigator Dr. Thomas McNamara, chief of vascular and interventional radiology at the University of California, Los Angeles Medical Center. "When you don't have overnight infusion, you almost never have bleeding."
The Lysus infusion system (EKOS Corporation, Bothell, WA) comprises a thin wire, beaded with up to 30 tiny ultrasound transducers, sheathed in a conventional catheter. Once it has been inserted in the affected area, the wire emits high-frequency, low-intensity waves as the catheter delivers the clot-busting drug, breaking thrombi's fibrin matrix apart. The manufacturer began testing with patients in Malmo, Sweden, in 1999 and secured FDA 510(k) market clearance in September 2004.
McNamara presented results from 13 U.S. institutions assessing the device. These centers have treated clots in 118 patients presenting with peripheral vascular occlusive disease. Available data on 62 patients with peripheral arterial disease and 33 patients with DVT show sonic lysis dissolved 87% and 70% of their clots, respectively, in less than 24 hours. Both patient groups also showed a 92% and 56% reduction in bleeding complications, respectively, compared with conventional treatment.
Conventional thrombolysis entails infusion at the site of the clot. Depending on thrombus size, it can take up to two days to complete. In addition, it is expensive and risky. Infusion times correlate heavily with potential limb- or life-threatening hemorrhage.
The new device enhances the ability to dissolve clots and may reduce complications, said Dr. James F. Benenati, director of the peripheral vascular lab at the Baptist Cardiac & Vascular Institute in Miami. Benenati's center is participating in the trial.
"It also may have the advantage of allowing the procedure to be done much more quickly, which will save physicians and hospitals time and lower the cost of the procedure," he said.
For more information from the Diagnostic Imaging archives:
Minimally invasive therapies break through in DVT
Revolution storms along in thrombolytic agents
Ultrasound shows promise for thrombosis treatment
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.